Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.05.036
Abstract: INTRODUCTION Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance mechanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR. However, the therapeutic effect of combining dabrafenib and… read more here.
Keywords: braf v600e; dabrafenib trametinib; v600e mutation; v600e ... See more keywords
A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
Sign Up to like & getrecommendations! Published in 2017 at "Pathology"
DOI: 10.1016/j.pathol.2017.08.011
Abstract: Melanoma patients with BRAF V600E and V600K mutations show complete or partial response to vemurafenib. Detection assays often scan for the common V600E mutation rather than the rare V600K variant, although this mutation can be… read more here.
Keywords: v600e v600k; level; v600k mutations; v600e ... See more keywords
MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.591
Abstract: Abstract INTRODUCTION Activation of the RAS-MAPK signaling cascade is common in pediatric gliomas. Based on the role of SHP2 in RAS pathway signaling, we hypothesized that NF1-deficient pediatric glioma models would respond to SHP2 inhibitor… read more here.
Keywords: braf v600e; gliomas; glioma; deficient ... See more keywords
Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma
Sign Up to like & getrecommendations! Published in 2018 at "Brain Pathology"
DOI: 10.1111/bpa.12473
Abstract: Ganglioglioma (GG) is a grade I tumor characterized by alterations in the MAPK pathway, including BRAF V600E mutation. Recently, diffuse midline glioma with an H3 K27M mutation was added to the WHO 2016 classification as… read more here.
Keywords: braf v600e; grade; v600e; k27m ... See more keywords
BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.17443
Abstract: BRAF T1799A mutation is the most common genetic variation in thyroid cancer, resulting in the production of BRAF V600E mutant protein reported to make cells resistant to apoptosis. However, the mechanism by which BRAF V600E… read more here.
Keywords: cell death; v600e; thyroid; braf v600e ... See more keywords
Detection of Circulating Tumor DNA in Patients with Thyroid Nodules
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Endocrinology"
DOI: 10.1155/2021/8909224
Abstract: Objective Detection of circulating tumor DNA (ctDNA) in cancer patients can potentially serve as a noninvasive, sensitive test of disease status. The purpose of this study was to determine the ability to detect BRAF (V600E)… read more here.
Keywords: braf v600e; thyroid nodules; v600e; ptc ... See more keywords
Abstract 19: Braf(v600e) mutation together with loss of trp53 or pten drives the origination of hairy cell leukemia from b-lymphocyte
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-19
Abstract: Hairy cell leukemia (HCL) is a B-lymphoma induced by BRAF(V600E) mutation. However, introducing BRAF(V600E) in B-lymphocytes fails to induce hematological malignancy, suggesting that BRAF(V600E) needs concurrent mutations for driving HCL ontogeny. To resolve this issue,… read more here.
Keywords: v600e; braf v600e; hairy cell;
Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Surgical Oncology"
DOI: 10.1245/s10434-020-08817-8
Abstract: Although the prognosis for patients with resected BRAF mutant colorectal liver metastases (CRLM) is poor, the survival impact of the BRAF V600E mutation in such cases remains unclear. A multicenter retrospective cohort study was performed… read more here.
Keywords: braf v600e; resected braf; study; v600e ... See more keywords
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Translational lung cancer research"
DOI: 10.21037/tlcr-21-415
Abstract: Background Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (NSCLC). However, the… read more here.
Keywords: braf v600e; resistance; v600e; lung cancer ... See more keywords
MRI-Based Texture Analysis for Preoperative Prediction of BRAF V600E Mutation in Papillary Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Multidisciplinary Healthcare"
DOI: 10.2147/jmdh.s393993
Abstract: Purpose BRAF V600E mutation can compensate for the low detection rate by fine-needle aspiration (FNA) and is related to aggressiveness and lymph node metastasis. This study aimed to investigate the relationship between texture analysis features… read more here.
Keywords: texture; analysis; braf v600e; mutation ... See more keywords
A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.800786
Abstract: Background In children, Langerhans cell histiocytosis (LCH), which is the most prevalent histiocytic disorder, exhibits a wide variety of manifestations and outcomes. There is no standard prognosis evaluation system for LCH. We investigated the combined… read more here.
Keywords: v600e; pfs; braf v600e; v600e map2k1 ... See more keywords